XNK Therapeutics AB Sweden

 

About XNK Therapeutics AB

XNK Therapeutics is a clinical stage immunotherapy company focused on bringing new and more effective treatments to cancer patients. The company is at the forefront of autologous NK cell-based cell therapy development with a proprietary technology platform and a pipeline spanning both hematological malignancies and solid tumor indications. The most advanced product, evencaleucel, is in phase II studies in combination with the CD38 antibody isatuximab targeting multiple myeloma. Other programs include XNK02 in AML, currently in advanced preclinical studies in collaboration with MD Anderson Cancer Center and XNK03 in bladder cancer, currently in preclinical studies in collaboration with the Karolinska University Hospital. XNK's efforts are supported by a dedicated team that include world-renowned NK cell experts and by an approved in-house GMP facility. XNK Therapeutics is headquartered in Stockholm, Sweden. For more info, please visit http://www.xnktherapeutics.com.  

The following files are available for download:

https://mb.cision.com/Main/16693/3909372/2538986.pdf

XNK Therapeutics receives EMA scientific recommendation for evencaleucel as an Advanced Therapy Medicinal Product

https://news.cision.com/xnk-therapeutics-ab/i/peter-hovstadius,c3257378

Peter Hovstadius

 

View original content:https://www.prnewswire.co.uk/news-releases/xnk-therapeutics-receives-ema-scientific-recommendation-for-evencaleucel-as-an-advanced-therapy-medicinal-product-302034513.html